结直肠腺瘤的共识分子亚型分类
该研究对62例腺瘤和59例结直肠癌进行RNA测序,并联合TCGA的556例结直肠癌数据,使用已建立的CMS分类器进行分型。结果显示87%的腺瘤可被分型,其中CMS3最常见(73%),CMS2占13%,CMS1占2%,无CMS4。CMS3富集于低进展风险腺瘤,而CMS2中高风险腺瘤相对更多。
要点
- 87%的结直肠腺瘤可被共识分子亚型(CMS)分类。
- 腺瘤中以CMS3代谢亚型为主(73%),CMS4未出现。
- CMS1和CMS2表达特征可能提示腺瘤进展风险增加。
核心结论
- 结直肠腺瘤可被分层为CMS类别,其分布与预期进展为结直肠癌的比例一致。
研究设计与样本
- 对62例腺瘤和59例结直肠癌进行RNA测序,联合TCGA的556例结直肠癌数据,使用已建立的CMS分类器进行分型。
主要发现
- 54/62(87%)的腺瘤被分类为CMS。
- CMS3在腺瘤中最常见(n=45;73%),在结直肠癌中最少见。
- 8例腺瘤(13%)分类为CMS2,2例MSI腺瘤中1例分类为CMS1(2%)。
- 无腺瘤分类为CMS4。
- CMS3富集于低进展风险腺瘤,CMS2中高风险腺瘤相对更多。
关键数值与推荐
- CMS3为腺瘤中最常见的亚型(73%),CMS2占13%,CMS1占2%,CMS4为0%。
临床怎么用
- 腺瘤的CMS分型可能有助于识别进展风险较高的腺瘤,CMS1和CMS2表达特征或提示风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Consensus molecular subtyping is an RNA expression-based classification system for colorectal cancer (CRC). Genomic alterations accumulate during CRC pathogenesis, including the premalignant adenoma stage, leading to changes in RNA expression. Only a minority of adenomas progress to malignancies, a transition that is associated with specific DNA copy number aberrations or microsatellite instability (MSI). We aimed to investigate whether colorectal adenomas can already be stratified into consensus molecular subtype (CMS) classes, and whether specific CMS classes are related to the presence of specific DNA copy number aberrations associated with progression to malignancy. RNA sequencing was performed on 62 adenomas and 59 CRCs. MSI status was determined with polymerase chain reaction-based methodology. DNA copy number was assessed by low-coverage DNA sequencing (n = 30) or array-comparative genomic hybridisation (n = 32). Adenomas were classified into CMS classes together with CRCs from the study cohort and from The Cancer Genome Atlas (n = 556), by use of the established CMS classifier. As a result, 54 of 62 (87%) adenomas were classified according to the CMS. The CMS3 'metabolic subtype', which was least common among CRCs, was most prevalent among adenomas (n = 45; 73%). One of the two adenomas showing MSI was classified as CMS1 (2%), the 'MSI immune' subtype. Eight adenomas (13%) were classified as the 'canonical' CMS2. No adenomas were classified as the 'mesenchymal' CMS4, consistent with the fact that adenomas lack invasion-associated stroma. The distribution of the CMS classes among adenomas was confirmed in an independent series. CMS3 was enriched with adenomas at low risk of progressing to CRC, whereas relatively more high-risk adenomas were observed in CMS2. We conclude that adenomas can be stratified into the CMS classes. Considering that CMS1 and CMS2 expression signatures may mark adenomas at increased risk of progression, the distribution of the CMS classes among adenomas is consistent with the proportion of adenomas expected to progress to CRC. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
引用
- Komor MA, Bosch LJ, Bounova G, et al. Consensus molecular subtype classification of colorectal adenomas. J Pathol. 2018. PMID: 29968252. doi:10.1002/path.5129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。